首页> 外文期刊>Transactions of the Royal Society of Tropical Medicine and Hygiene >Melioidosis: acute and chronic disease, relapse and re-activation.
【24h】

Melioidosis: acute and chronic disease, relapse and re-activation.

机译:拟鼻病:急慢性疾病,复发和重新激活。

获取原文
获取原文并翻译 | 示例
       

摘要

In melioidosis-endemic regions the importance of re-activation of Burkholderia pseudomallei from latent foci remains unclear. This topic was assessed in a 10-year prospective study (1989-99) of melioidosis in the tropical north of the Northern Territory of Australia, together with other aspects of the nature of melioidosis. Incubation period from defined inoculating events was previously ascertained as 1-21 (mean 9) days. Of 252 total cases 244 (97%) were considered to be from recent acquisition of B. pseudomallei infection and 8 (3%) were considered to be re-activation from a latent focus. Acute illness occurred in 222 (88%) cases; 30 (12%) cases had chronic illness (symptomatic for > 2 months). Of the 207 patients surviving the initial illness, 27 (13%) had a confirmed relapse (mean time from initial diagnosis of 8 months), with 5 relapsing twice. Of these 32 relapses, 15 (3 fatal) were associated with poor adherence to the eradication therapy antibiotics and 10 (none fatal) were failures of eradication with doxycycline monotherapy. Following initial intensive therapy with ceftazidime or meropenem for at least 14 days, eradication therapy with trimethoprim-sulphamethoxazole monotherapy for at least 3 months had been more successful.
机译:在类疟疾流行地区,从潜在病灶中重新激活假阳性伯克霍尔德菌的重要性仍不清楚。在澳大利亚北领地北部热带地区进行的为时10年的前肢类黑斑病前瞻性研究(1989-99年)中,评估了这个主题,同时还评估了类黑斑病的其他特征。预先确定的接种事件的潜伏期事先确定为1-21天(平均9天)。在252例病例中,有244例(97%)被认为是来自最近获得的假性马来芽孢杆菌感染,而8例(3%)被认为是从潜在病灶中重新激活的。 222例(88%)病例为急性疾病; 30例(12%)患有慢性病(有症状的> 2个月)。幸存的初次生存的207例患者中,有27例(13%)确诊复发(从初次诊断到平均8个月的时间),其中5例复发两次。在这32例复发中,有15例(3例致命)与根除疗法对抗生素的依从性差有关,而10例(无致命)与强力霉素单一疗法的根除失败有关。最初用头孢他啶或美洛培南进行密集治疗至少14天后,用甲氧苄啶-磺胺甲恶唑单药根除治疗至少3个月更为成功。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号